<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The performance of combining fecal immunochemical tests (FITs) and a high-risk factor questionnaire (HRFQ) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) screening in economically and medically underserved populations is uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the performance of a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening protocol of combining FITs and an HRFQ as primary screening methods in a rural Chinese population </plain></SENT>
<SENT sid="2" pm="."><plain>A <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mass screening was conducted using FITs and an HRFQ as the first and colonoscopy as the second stage of screening in Jiashan, 2007-2009 </plain></SENT>
<SENT sid="3" pm="."><plain>The target population was 31,963 residents in three communities </plain></SENT>
<SENT sid="4" pm="."><plain>The compliance was 84.7% for HRFQ, 76.4% for FITs, and 78.7% for colonoscopy </plain></SENT>
<SENT sid="5" pm="."><plain>The detected rates of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:mpath ids='MPATH_270'>adenoma</z:mpath>, nonadenomatous <z:mpath ids='MPATH_491'>polyps</z:mpath>, and advanced <z:hpo ids='HP_0002664'>neoplasm</z:hpo> were 2.7%, 14.8%, 5.9%, and 8.9% by FITs, which were higher than those by HRFQ (0.5%, 9.2%, 4.8%, and 3.8%, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>There was no significant difference in detected rate for nonadenomatous <z:mpath ids='MPATH_491'>polyps</z:mpath> between FITs and HRFQ </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 41.2% <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 53.2% nonadenomatous <z:mpath ids='MPATH_491'>polyps</z:mpath>, and 29.8% advanced <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were detected by HRFQ but missed by FITs </plain></SENT>
<SENT sid="8" pm="."><plain>Positive predictive value of the screening protocol of combining FITs and HRFQ for advanced <z:hpo ids='HP_0002664'>neoplasm</z:hpo> was 5.7%, which was higher than FITs alone </plain></SENT>
<SENT sid="9" pm="."><plain>Men had a higher prevalence of advanced <z:hpo ids='HP_0002664'>neoplasm</z:hpo> than women </plain></SENT>
<SENT sid="10" pm="."><plain>Results indicate that combining FITs and HRFQ as primary screening methods is an efficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening strategy in economically and medically underserved populations </plain></SENT>
</text></document>